Bayer said it was targeting growth in adjusted core profit of 7% to 9.6% this year, driven by sales of agriculture products and pharmaceuticals, despite facing multiple legal cases in the US over cancer claims.

BAYER look set to win the bid for drugmaker Schering, at €16.3 billion, after rival Merck pulled out of the race for top spot in Germany’s drugs industry.